Estradiol / micronised progesterone
Indication
Continuous combined hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses
Green (Restricted)
Brand:
Bijuve
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Estradiol (as estradiol hemihydrate) and progesterone 1mg/100mg Soft Capsules (Bijuve®) for continuous combined hormone replacement therapy (HRT) is recommended for initiation and ongoing prescribing in both primary and secondary care provided that:
-
- Bijuve® is an alternative when other HRT treatments have not been tolerated or when Femoston-Conti® is being considered OR
- Bijuve® replaces HRT regimens where separate oestrogen and micronised progesterone are used (single hormone products used in combination are more expensive than Bijuve®).
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: